Interim report January – September 2022 for CombiGene AB (publ)

July – September 2022
•  Net sales: 5,213 (0) TSEK.
•  Other operating revenues: 8,313 (423) TSEK.
•  Profit from financial items: 3,953 (-10,225) TSEK.
•  Earnings per share: 0.20 (-0.52) SEK.

January – September 2022
•  Net sales: 21,354 (0) TSEK.
•  Other operating revenues: 21,280 (6,380) TSEK.
•  Profit from financial items: 5,785 (-36,483) TSEK.
•  Earnings per share: 0.29 (-2.22) SEK.
•  Cash and cash equivalents as per the end of the reporting period: 144,940 (66,087) TSEK.
•  Equity ratio as per the end of the reporting period: 96 (95)%.

Events during the period
• CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO.

Events after the end of the period
• There have been no significant events after the end of the period.

Link to the report

Share